低分子肝素治疗不同证型脑梗死疗效比较

The Comparison on the Therapeutic Effect of Low Molecular Weight Heparin for Acute Cerebral Infarction,of Different Syndrome Types in TCM

目的观察脑梗死不同证型对低分子肝素(LWMH)的疗效反应。方法将176例急性脑梗死随机分为LWMH治疗组与常规治疗组,再进一步将两组分为LWMH治疗血瘀组、LWMH治疗非血瘀组和常规治疗血瘀组、常规治疗非血瘀组共四组,以治疗前后欧洲卒中量表(ESS)和日常生活能力量表(ADL)的分数差值作为疗效观察指标。结果LWMH治疗组和常规治疗组在治疗后10d的ESS分数差值无显著性差异,但治疗后21d两组的ESS分数差值差异显著;治疗后21dLWMH治疗血瘀组的ESS分数差值与其余三组比较有显著性差异;治疗后21d所有组间的ADL分数差值无显著性差异。结论LWMH对急性脑梗死血瘀证患者有更好的疗效。

Objective： To investigate the therapeutic effect of lwo molecular weight heparin （LWMH） on acute cerebral infarction, of different Syndrome Types in TCM. Methods： 176 patients were randomly assigned into 2 groups firstly, the LWMH group treated with LWMH, the control group treated with Aspirin. And then divided the group into 4 different Syndrome Types in TCM groups according to the diagnostic standard of Blood Stasis Syndrome （BSS）. The European Stroke Scale （ESS） and the Ability of Daily Life （ADL） at 10 and 21 days after onset of stroke were used as effective parameters. Results： There was no significant difference of the score of ESS at the 10th day after the treatment between the LWMH group and the control group. The ESS improvement at the 21th day was significantly higher in the LWMH group than that in the control group. At the 2hh day, the ESS score of the LWMH group with BSS was significantly higher than that of the LWMH group with non - BSS, the control group with BSS and the control group with non - BSS. There was no significant difference of the score of ADL at the 21th day between all these groups. Conclusion： LWMH has more therapeutic effect in treating patients of acute cerebral infarction with BSS.